item management s discussion and analysis of financial condition and results of operations overview the company initially focused its efforts on establishing collaborative arrangements  establishing and expanding its gene sequencing  bioinformatics  molecular biology  cell biology  protein expression and pharmacology capabilities  developing proprietary processes for automating the gene discovery process and creating  together with its collaborators  approximately cdna libraries representing most human organs  tissues and cell types 
the company s activities are focused primarily on research and development of therapeutic protein product candidates 
the company has not received any product sales revenue or royalties from product sales and does not anticipate revenues from product sales or from royalties on product sales in the foreseeable future 
through december   the company had received i million in revenue and million in equity payments pursuant to the sb collaboration agreements  ii payments from the new collaboration partners of million and iii an aggregate of million from other collaborators  including million from pioneer hi bred international  inc pioneer  million from f 
hoffmann la roche roche  million from pharmacia upjohn company pharmacia  million from oravax merieux co 
and merieux oravax snc collectively  oravax and million from schering plough in addition to certain payments received from schering plough pursuant to the new collaboration partner agreements 
pursuant to the terms of such collaboration agreements  the company expects to receive license fees and research payments of million annually over the next four years from the new collaboration partners and an aggregate of million over the next four years from other collaborators 
see business collaborative arrangements 
the company expects that its revenue sources for at least the next several years may be limited to interest income  payments under the collaboration agreements with the new collaboration partners  payments from the sale of rights and other payments from other collaborators and licensees under existing or future arrangements  to the extent that the company enters into any such further arrangements 
the company expects to continue to incur substantial expenses relating to its research and development efforts  which are expected to increase relative to historical levels as the company focuses on preclinical and clinical trials required for the development of therapeutic protein product candidates 
as a result  the company expects to incur continued and increasing losses over the next several years unless it is able to realize additional revenues under existing or new collaboration agreements 
the timing and amounts of such revenues  if any  cannot be predicted with certainty and will likely fluctuate sharply 
results of operations for any period may be unrelated to the results of operations for any other period 
in addition  historical results should not be viewed as indicative of future operating results 
results of operations years ended december  and revenues 
the company had revenues of million and million for the years ended december  and december   respectively 
the revenue consisted of million for the achievement of the third milestone milestone iii under the sb collaboration agreements  million in license fees and research payments from collaborations with pioneer and roche entered into in the first quarter of  million in annual license fees and additional payments from collaborations with schering plough and synthelabo entered into in the second quarter of  million in annual license fees and additional payments pursuant to a collaboration agreement entered into with merck in july  and million in license fees from collaborations with pharmacia  medimmune and oravax entered into in the fourth quarter of the revenue consisted of million from takeda for an option and license agreement to commercialize certain future products of the company in japan 
expenses 
research and development expenses increased to million for the year ended december  from million for the year ended december  the increase resulted primarily from significant expansions in the company s cell biology  protein expression and pharmacology departments and reflect the company s increasing emphasis on determining the biological functions and possible medical utilities of genes and proteins discovered as a result of the company s gene discovery efforts 
expenses will continue to increase in support of research and development of potential products by the company and in support of the new collaborations 
general and administrative expenses increased to million for the year ended december  from million for the year ended december  the increase resulted primarily from significantly higher legal expenses associated with filing and prosecuting a larger number of patent applications relating to genes and proteins discovered by the company 
patent expenses will continue to increase significantly as additional applications are filed and existing applications are prosecuted in the united states and internationally 
interest income was significantly higher for the year ended december  compared to the year ended december  due to higher cash balances and interest rates 
net income loss 
the company recorded a net loss of million  or per share  for the year ended december  compared to a net loss of million  or per share  for the year ended december  the difference in results for the year ended december  and is primarily due to the receipt of million in license fees and research payments during the year ended december   which was partially offset by higher expenses 
years ended december  and december  revenues 
the company generated million in revenues for the year ended december   compared with revenues of million for the year ended december  the revenues were received from takeda for an option and license agreement to commercialize certain future products of the company in japan 
substantially all of the revenues were payments upon the achievement of the first milestone milestone i first quarter and the second milestone milestone ii second quarter under the sb collaboration agreements  and the exercise by sb of an option for certain rights in southeast asia  pursuant to the sb collaboration agreements 
expenses 
research and development expenses were million for the year ended december   compared to million for the year ended december  the company s payments to tigr increased from million in to million in due primarily to higher scheduled research payments in accordance with the long term contractual agreement between tigr and the company 
direct expenditures for research and development increased to million for the year ended december  from million for the year ended december  due to planned expansions in the areas of molecular biology  cell biology  protein expression and pharmacology 
general and administrative expenses increased to million for the year ended december  from million for the year ended december  to support the increase in the company s activities 
patent expenses increased significantly as additional applications were filed and existing applications were prosecuted in the united states and internationally 
interest income was significantly higher for the year ended december  compared to the year ended december  due to higher interest rates and cash balances 
net income loss 
the company reported a net loss of million  or per share  for the year ended december  compared to net income of million  or per share  for the year ended december  this difference is primarily due to the considerably higher revenues recorded during compared to coupled with higher overall expenses during compared to liquidity and capital resources the company had working capital plus long term investments  which include obligations of the us government and commercial paper that have maturities greater than months from the balance sheet date  of million at december  as compared to million at december  the increase resulted from the sale of  shares of common stock to smithkline beecham for million upon completion of milestone iii under the sb collaboration agreements  which was partially offset by the net loss generated during the year  capital expenditures  and payments on capitalized leases 
in addition  in march the company received net proceeds of million after underwriting discounts and commissions and estimated offering expenses from a public offering of  shares of common stock at a public offering price of per share 
the company expects to continue to incur substantial expenses relating to its research and development efforts  which expenses are expected to increase relative to historical levels as the company focuses on preclinical and clinical trials required for the development of therapeutic protein product candidates 
as of december   the company is committed to pay tigr approximately million during the next six years  including approximately million through december  at december   the company had outstanding commitments for construction and equipment purchases totaling approximately  in addition  the company is planning the construction of a pilot scale production and process development facility and intends to seek financing with respect to all or a portion of the estimated million construction cost of such facility 
there can be no assurance that the company will be able to obtain any such financing on terms acceptable to the company  or at all 
in the event that financing is not available on acceptable terms  the company may determine to use its own capital resources to finance all or a portion of the cost of such facility 
the company expects that its existing funds  including proceeds from the offering in march interest income  and committed license fees and research payments from the new collaboration partners and under existing collaboration agreements will be sufficient to fund the company s operations for the foreseeable future 
the company s future capital requirements and the adequacy of its available funds will depend on many factors  including scientific progress in its research and development programs  the magnitude of those programs  the ability of the company to establish collaborative and licensing arrangements  the cost involved in preparing  filing  prosecuting  maintaining and enforcing patent claims and competing technological and market developments 
as of december   the company had net operating loss carryforwards for federal income tax purposes of approximately million the majority of which expire  if unused  in the year the company also has available research and development tax credit carryforwards of approximately million  the majority of which will expire  if unused  between the years and the company s funds are currently invested in us treasury and government agency obligations  investment grade commercial paper and interest bearing securities 
such investment reflects the company s policy regarding the investment of liquid assets  which is to seek a reasonable rate of return consistent with the emphasis on safety  liquidity and preservation of capital 
safe harbor statement under the private securities litigation reform act of certain statements contained in item business and item management s discussion and analysis of financial condition and results of operations  including statements concerning future collaboration agreements  royalties and other payments under collaboration agreements  and product development and sales and other statements are forward looking statements  as defined in the private securities litigation reform act of actual results may differ materially from those projected in the forward looking statements as a result of risks and uncertainties  including but not limited to  the following the scientific progress of the company in its research and development programs  the magnitude of these programs  the ability of the company to establish additional collaborative and licensing arrangements  the extent to which the company engages in clinical development of any products on its own  the scope and results of pre clinical testing and clinical trials  the time and costs involved in obtaining regulatory approvals  the costs involved in preparing  filing  prosecuting  maintaining and enforcing patent claims  competing technological and market developments  and whether conditions to milestone payments are met and the timing of such payment  and other risks and uncertainties detailed elsewhere herein and from to time in the company s filings with the securities and exchange commision 

